Compile Data Set for Download or QSAR
Report error Found 51 Enz. Inhib. hit(s) with all data for entry = 11004
TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585064(US11529347, Compound 42)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384130(US10280171, Example 16 | (1-(3-(4-chloro- phenyl)-...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585052(US11529347, Compound 30)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384134(US10280171, Example 20 | 1-(3-(2- Chlorophenyl)-1H...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585054(US11529347, Compound 32)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585055(US11529347, Compound 33)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585056(US11529347, Compound 34)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585057(US11529347, Compound 35)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585060(US11529347, Compound 38)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384141(US10280171, Example 27 | (1-(3-(2-chloro-3- methox...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585062(US11529347, Compound 40)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585063(US11529347, Compound 41)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384124(US10280171, Example 10 | 1-(3-(3-chloro- phenyl)-1...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384143(US10280171, Example 29 | (1-(3-(2-chloro- phenyl)-...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585066(US11529347, Compound 44)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585068(US11529347, Compound 46)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585069(US11529347, Compound 47)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384139(US10280171, Example 25 | (1-(3-(3-Chloro-2-fluorop...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384123(US10280171, Example 9 | (1-(3-(3-chloro- phenyl)-1...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585073(US11529347, Compound 51)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384173(US10280171, Example 60 | 4-(aminomethyl)-1- (3-(2-...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585076(US11529347, Compound 54)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384174(US10280171, Example 61 | (4-amino-1-(3-(2- chlorop...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384167(US10280171, Example 54 | (R)-8-(3-(2- chlorophenyl...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384140(US10280171, Example 26 | 1-(3-(3-chloro-2- fluorop...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585006(US11529347, Compound 9)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM576022(US11529347, Compound 10 | US11466017, Example 9 | ...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585034(US11529347, Compound 12)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585035(US11529347, Compound 13)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585037(US11529347, Compound 15)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585050(US11529347, Compound 28)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384129(US10280171, Example 15 | 1-(3-(4-Chlorophenyl)-1H-...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585040(US11529347, Compound 18)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585041(US11529347, Compound 19)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585046(US11529347, Compound 24)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585049(US11529347, Compound 27)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585048(US11529347, Compound 26)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585047(US11529347, Compound 25)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585042(US11529347, Compound 20)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM384117(US10280171, Example 1 | 1-(3-(2,3-dichlorophenyl)-...)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585043(US11529347, Compound F21)
Affinity DataIC50: 1.00E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585036(US11529347, Compound 14)
Affinity DataIC50: 5.50E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585044(US11529347, Compound 22)
Affinity DataIC50: 5.50E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585071(US11529347, Compound 49)
Affinity DataIC50: 5.50E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585030(US11529347, Compound 11)
Affinity DataIC50: 5.50E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585058(US11529347, Compound 36)
Affinity DataIC50: 5.50E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585059(US11529347, Compound 37)
Affinity DataIC50: 5.50E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585075(US11529347, Compound 53)
Affinity DataIC50: 5.50E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585003(US11529347, Compound 8)
Affinity DataIC50: 5.50E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

TargetTyrosine-protein phosphatase non-receptor type 11(Human)
Relay Therapeutics

US Patent
LigandPNGBDBM585077(US11529347, Compound 55)
Affinity DataIC50: 5.50E+4nMAssay Description:SHP2 is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation st...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 51 total ) | Next | Last >>
Jump to: